A szisztémás lupus erythematosus epidemiológiai tényezőinek vizsgálata Magyarországon
Kedves Melinda
Molecular Medicine
Dr. Enyedi Péter
OMINT Közösségi Központ
2025-02-26 15:00:00
Human molecular genetics and genetic diagnostics
Dr. Wiener Zoltán
Dr. Nagy György
Dr. Balog Attila
Dr. Minier Tünde
Dr. Kalabay László
Dr. Nagy Eszter
Dr. Szamosi Szilvia Katalin
In our work, we analyzed the epidemiological data of SLE in Hungary using the NEAK database, examining 7888 patients between January 1, 2008, and June 30, 2017. Among them, we identified 4503 new incident cases (A group) and 2582 treated patients ("Treated SLE Patients" group). The annual prevalence increased (from 36.1 to 70.5/100,000). Women predominated in both groups (85%), with average ages of 46 and 47 years. The data suggests that SLE incidence and prevalence in Hungary are similar to European population, especially among Caucasians.
We examined SLE mortality data compared to age- and gender-matched non-SLE control population. The SMR was 1.63 for "All Incident SLE Patients" and 2.09 for "Treated SLE Patients" group. The estimated survival probability from diagnosis was 98.0% in the first year for both groups. By the third year, it decreased to 95.0% and 94.0%, respectively, and by the fifth year to 91.8% and 89.6%. SLE patient survival was significantly lower (p<0.001) compared to the control population.
We also investigated causes of death alongside mortality data and survival curves. We identified four disease groups: cardiovascular, cerebrovascular, infections, and tumor diseases. Examining life-threatening conditions was crucial. In our study, infections were the most common cause of death among SLE patients compared to the control population. Within the infection, sepsis caused additional mortality.
We determined the Charlson Comorbidity Index (CCI) in the two years preceding and following the first SLE diagnosis for both SLE patients and the control group. SLE patients showed higher CCI values (p<0.001) in both periods.
